VTCN1 Antikörper (PE)

Produktnummer ABIN2662392

Produktdetails anti-VTCN1 Antikörper (PE)

Target: VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1))

Reaktivität: Maus

Wirt: Armenischer Hamster

Klonalität: Monoklonal

Konjugat: Dieser VTCN1 Antikörper ist konjugiert mit PE

Applikation: Flow Cytometry (FACS)

Aufreinigung: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Klon: HMH4-5G1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Protect from prolonged exposure to light. Do not freeze.

Lagerung: 4 °C

Informationen zur Lagerung: The antibody solution should be stored undiluted between 2°C and 8°C.

Details zu VTCN1

Target: VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1 (VTCN1))

Andere Bezeichnung: B7-H4 B7S1 (VTCN1 Produkte)

Hintergrund: B7-H4 is a newly discovered B7 family member that negatively regulates T cell immunity. In vitro, B7-H4 inhibits CD4+ and CD8+ T cell proliferation, cytokine production, and generation of alloreactive cytotoxic T-cells (CTLs). In vivo, blockage of endogenous B7-H4 by specific monoclonal antibodies promotes T cell responses. A new reported function of B7-H4 is as an important negative regulator of innate immunity through growth inhibition of neutrophils. It has been reported that B7-H4 is not constitutively expressed on peripheral tissues but can be induced to express on T cells, B cells, macrophages, and dendritic cells. B7-H4 is expressed on some tumor cancer cells. The role of B7-H4 in tumor progression may be to transform precancerous cells and then protect them from immunosurveillance. Although B- and T-lymphocyte attenuator (BTLA) was proposed to be the receptor for B7-H4, further studies are needed to identify the inhibitory receptor of B7-H4.